Related Experiment Video
Updated: Sep 9, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.2K
Predicting Alzheimer's Disease Progression from Sparse Multimodal Data by NeuralODE Models.
Andrea Zanin1,2, Stefano Pagani2, Mattia Corti2
1IoTique, V.le Trento 37D, Rovereto, 38062, TN, Italy.
Biorxiv : the Preprint Server for Biology
|September 5, 2025
Summary
This study introduces a new AI model to predict Alzheimer's disease progression using limited patient data. The model improves early diagnosis and tracks biomarker changes for better neurodegenerative disease monitoring.
Area of Science:
- Neuroscience
- Artificial Intelligence
- Biomedical Data Science
Background:
- Alzheimer's disease (AD) progression varies significantly among patients, complicating diagnosis and care.
- Current data-driven models often require extensive, specific datasets not readily available in clinical settings.
- Accurate prediction of individual disease trajectories is crucial for effective management of neurodegenerative disorders.
Purpose of the Study:
- To develop a novel modeling framework for predicting individual Alzheimer's disease trajectories.
- To utilize sparse, irregularly sampled, multi-modal clinical data for disease progression modeling.
- To enhance early diagnosis and monitoring of neurodegenerative diseases.
Main Methods:
- Implementation of (recurrent) Neural Ordinary Differential Equations (NODEs).
- Forecasting patient disease progression and biomarker evolution over time.
- Utilizing sparse, multi-modal clinical data for model training and validation.
Main Results:
- The developed model accurately detected early signs of Alzheimer's disease.
- It effectively tracked changes in biomarker trajectories, aligning with clinical knowledge.
- Demonstrated superior performance compared to common data-driven alternatives on the ADNI cohort.
Conclusions:
- The proposed modeling framework offers a versatile tool for personalized Alzheimer's disease diagnosis and monitoring.
- This approach addresses the limitations of existing models in handling sparse, real-world clinical data.
- The findings support the potential of AI in advancing the management of neurodegenerative diseases.
Related Concept Videos
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Neural Regulation
39.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.8K

